Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triamcinolone acetonide sustained release - Flexion Therapeutics

Drug Profile

Triamcinolone acetonide sustained release - Flexion Therapeutics

Alternative Names: FX-006; Triamcinolone acetonide extended release - Flexion Therapeutics; Zilretta

Latest Information Update: 03 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Flexion Therapeutics
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain
  • Phase II Periarthritis

Most Recent Events

  • 10 Jan 2022 University of North Carolina and Flexion Therapeutics completes a phase I trial in Musculoskeletal pain (associated with knee osteoarthritis) in USA (Intra-articular) (NCT04261049)
  • 05 Jan 2022 Initial efficacy and safety data from a phase III trial in Musculoskeletal pain presented at the American College of Rheumatology Convergence (ACR-2021)
  • 09 Aug 2021 Pharmacokinetics data from a phase II SHIP trial in Musculoskeletal pain (associated with osteoarthritis of the hip and shoulder) released by Flexion Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top